Regeneron Pharmaceuticals, Inc.
Corporate Headquarters
777 Old Saw Mill River Road
Tarrytown
New York
10591
United States
Tel: 914-847-7000
Website: http://www.regeneron.com/
About Regeneron Pharmaceuticals, Inc.
Regeneron (NASDAQ: REGN) is a leading science and technology company delivering life-transforming medicines for serious diseases.
Founded by physician-scientists 30 years ago, our science-driven approach has resulted in six FDA-approved medicines and numerous product candidates in a range of diseases, including asthma, pain, cancer and infectious diseases.
In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human genetics sequencing efforts in the world and rapid response technologies being used for global good.
Additional locations:
Basking Ridge (Clinical Operations & Biostats)
110 Allen Road
Basking Ridge, NJ 07920
+1 914-847-7000
Industrial Operations and Product Supply
81 Columbia Turnpike
Rensselaer, NY 12144
+1 518-488-6000
777 articles with Regeneron Pharmaceuticals, Inc.
-
Winter and the Holidays are right around the corner, but don't stop your job search! Check out the top companies who are looking for candidates like you right now!
-
The U.S. public apparently believes that drug prices are too high. At the same time, they seem largely opposed to government efforts to control health care costs, alternately supportive and non-supportive of efforts to eliminate the Affordable Care Act, better known as Obamacare.
-
A Look at a Few ASH Highlights: Gilead/Kite, Novartis, Celgene, Bluebird Bio, Seattle Genetics
12/3/2018
The American Society of Hematology Annual Meeting is always chock full of interesting research and development stories. Here’s a look at some of the highlights of the meeting so far, which is continuing today. -
Regeneron Presents Positive Data at ASH for REGN1979 CD20xCD3 Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
12/1/2018
100% overall and 80% complete response rate in 10 patients with relapsed or refractory follicular lymphoma treated with 5 mg or more of REGN1979
-
Regeneron Announces Upcoming Investor Conference Presentation on November 27, 2018
11/20/2018
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its management presentation at the Piper Jaffray 30th Annual Healthcare Conference at 11:00 a.m. ET on Tuesday, November 27, 2018.
-
As Deadliest Strain Ravages Country, Four Experimental Ebola Vaccines to Be Deployed in the Congo
11/12/2018
As an outbreak of the Ebola virus in the Democratic Republic of the Congo worsens, a team of health officials has taken four experimental vaccines to the front lines and begun to administer it to patients who may have been exposed to the deadly virus. -
ODYSSEY OUTCOMES Investigators Highlight at AHA that Praluent® (alirocumab) Injection Was Associated with Fewer Deaths from Any Cause
11/11/2018
Mortality risk reduction greater in patients treated for at least 3 years or those with baseline LDL-C levels of at least 100 mg/dL
-
Boston Business Journal recently created a list of 15 Massachusetts life science companies that in their third-quarter reports, allocated the highest percentage of total costs to research and development. Here’s a look.
-
FDA Grants Priority Review for Dupixent® (dupilumab) as Potential Treatment for Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis
11/6/2018
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) in adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis, whose disease was inadequately controlled with topical therapies or for whom topical treatment was medically inadvisable.
-
Clearside Biomedical Shares Plunge as Phase III Xipere Failure Forces the Company to Discontinue ...
11/5/2018
Clearside CEO says the company will discontinue two studies that pair Xipere with Eylea following the Phase III failure. -
Top 12 Life Science Companies Hiring Now
11/2/2018
Fall is in full swing, but not falling short of jobs. Check out the top companies who are looking for candidates like you right now! -
Biopharma companies set to release financial reports next week have reported positive news in recent months.
-
In its recent third-quarter report, Cambridge, Mass.-based Intellia Therapeutics indicated it is delaying its submission of an Investigational New Drug (IND) application until 2020, from late 2019.
-
Nearly two weeks after the U.S. Food and Drug Administration approved Sanofi and Regeneron’s Dupixent as an add-on maintenance therapy for moderate to severe asthma, the France-based company reported a surge in sales for the medication in its most recent quarterly report.
-
Roche announced positive data from its Phase II STAIRWAY clinical trial. The trial evaluated the extended durability of faricimab (RG7716) in the treatment of neovascular (wet) age-related macular degeneration (nAMD).
-
Novartis nAMD Treatment Brolucizumab Shows Superiority Against Regeneron’s Eylea at Two Years
10/29/2018
With fresh two-year data in hand, Novartis remains focused on seeking regulatory approval for brolucizumab, an ophthalmology drug for the treatment of neo-vascular age related macular degeneration.. -
In a survey of more than 8,000 people in the biotech and pharma industry for Science, Regeneron Pharmaceuticals, topped the list.
-
Regeneron Ranked #1 Biopharma Employer for Sixth Time by Science Magazine
10/26/2018
Company Also Celebrates Second Annual Global Day of Service.
-
EYLEA® (aflibercept) Injection Improves Diabetic Retinopathy and Reduces Vision-Threatening Complications in Phase 3 Trial
10/25/2018
First trial in non-proliferative diabetic retinopathy to show both a reduction in vision-threatening complications and in development of diabetic macular edema
-
Regeneron Pharmaceuticals’ Eylea (aflibercept) showed strongly positive data in a Phase III trial in patients with moderately severe and severe non-proliferative diabetic retinopathy (NPDR). The trial met its 52-week primary endpoint and key secondary endpoints.